% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Scuteri:163496,
      author       = {Scuteri, Damiana and Contrada, Marianna and Tonin, Paolo
                      and Corasaniti, Maria Tiziana and Nicotera, Pierluigi and
                      Bagetta, Giacinto},
      title        = {{D}ementia and {COVID}-19: {A} {C}ase {R}eport and
                      {L}iterature {R}eview on {P}ain {M}anagement.},
      journal      = {Pharmaceuticals},
      volume       = {15},
      number       = {2},
      issn         = {1424-8247},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DZNE-2022-00256},
      pages        = {199},
      year         = {2022},
      abstract     = {The coronavirus disease 2019 (COVID-19) pandemic imposes an
                      unprecedented lifestyle, dominated by social isolation. In
                      this frame, the population to pay the highest price is
                      represented by demented patients. This group faces the
                      highest risk of mortality, in case of severe acute
                      respiratory syndrome coronavirus (SARS-CoV-2) infection, and
                      they experience rapid cognitive deterioration, due to
                      lockdown measures that prevent their disease monitoring.
                      This complex landscape mirrors an enhancement of
                      neuropsychiatric symptoms (NPSs), with agitation, delirium
                      and reduced motor performances, particularly in
                      non-communicative patients. Due to the consistent link
                      between agitation and pain in these patients, the use of
                      antipsychotics, increasing the risk of death during
                      COVID-19, can be avoided or reduced through an adequate pain
                      treatment. The most suitable pain assessment scale, also
                      feasible for e-health implementation, is the
                      Mobilization-Observation-Behaviour-Intensity-Dementia
                      (MOBID-2) pain scale, currently under validation in the
                      Italian real-world context. Here, we report the case of an
                      85-year-old woman suffering from mild cognitive impairment,
                      subjected to off-label treatment with atypical
                      antipsychotics, in the context of undertreated pain, who
                      died during the pandemic from an extensive brain hemorrhage.
                      This underscores the need for appropriate assessment and
                      treatment of pain in demented patients.},
      keywords     = {COVID-19 (Other) / MOBID-2 (Other) / NPSs (Other) /
                      dementia (Other) / pain assessment (Other) /
                      tele-neurorehabilitation (Other)},
      cin          = {AG Bano / Scientific board},
      ddc          = {610},
      cid          = {I:(DE-2719)1013003 / I:(DE-2719)1030000},
      pnm          = {351 - Brain Function (POF4-351)},
      pid          = {G:(DE-HGF)POF4-351},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:35215311},
      pmc          = {pmc:PMC8879883},
      doi          = {10.3390/ph15020199},
      url          = {https://pub.dzne.de/record/163496},
}